Avinash G Dinmohamed1, Otto Visser2, Yvette van Norden3, Peter C Huijgens4, Pieter Sonneveld1, Arjan A van de Loosdrecht4, Mojca Jongen-Lavrencic5. 1. Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. 2. Department of Registration and Research, Comprehensive Cancer Centre The Netherlands, Utrecht, The Netherlands. 3. Clinical Trial Center, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. 4. Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands. 5. Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: m.lavrencic@erasmusmc.nl.
Abstract
BACKGROUND: Studies with long-term follow-up of patients with myelodysplastic syndromes (MDS) based on data from nationwide population-based cancer registries are lacking. We conducted a nationwide population-based study to assess trends in incidence, initial treatment and survival in MDS patients diagnosed in the Netherlands from 2001 to 2010. METHODS: We identified 5144 MDS patients (median age, 74 years) from the Netherlands Cancer Registry (NCR). The NCR only includes MDS cases that were confirmed by bone marrow examinations. Information regarding initial treatment decisions was available in the NCR. RESULTS: The age-standardised incidence rate of MDS was 2.3/100,000 in 2001-2005 and 2.8/100,000 in 2006-2010. The incidence increased with older age, with the highest incidence among those aged ≥80 years (32.1/100,000 in 2006-2010). Forty-nine percent of all MDS cases were unspecified. Of all patients, 89% receive no treatment or only supportive care and 8% were started on intensive therapy as initial treatment. Survival did not improve over time. The 5-year relative survival was 53%, 58%, 48%, 38% and 18% in patients with refractory anaemia (RA), RA with ringed sideroblasts, 5q-syndrome, refractory cytopenia with multilineage dysplasia, and RA with excess blasts, respectively. CONCLUSION: The incidence of MDS increased over time due to improved notification and better disease awareness, and has stabilised since 2007. The classification of MDS seems challenging as almost half of the pathologically confirmed cases were unspecified. The lack of improvement in survival might be explained by the limited availability of therapeutic agents. Therefore, ameliorated management and new treatment options are warranted.
BACKGROUND: Studies with long-term follow-up of patients with myelodysplastic syndromes (MDS) based on data from nationwide population-based cancer registries are lacking. We conducted a nationwide population-based study to assess trends in incidence, initial treatment and survival in MDSpatients diagnosed in the Netherlands from 2001 to 2010. METHODS: We identified 5144 MDSpatients (median age, 74 years) from the Netherlands Cancer Registry (NCR). The NCR only includes MDS cases that were confirmed by bone marrow examinations. Information regarding initial treatment decisions was available in the NCR. RESULTS: The age-standardised incidence rate of MDS was 2.3/100,000 in 2001-2005 and 2.8/100,000 in 2006-2010. The incidence increased with older age, with the highest incidence among those aged ≥80 years (32.1/100,000 in 2006-2010). Forty-nine percent of all MDS cases were unspecified. Of all patients, 89% receive no treatment or only supportive care and 8% were started on intensive therapy as initial treatment. Survival did not improve over time. The 5-year relative survival was 53%, 58%, 48%, 38% and 18% in patients with refractory anaemia (RA), RA with ringed sideroblasts, 5q-syndrome, refractory cytopenia with multilineage dysplasia, and RA with excess blasts, respectively. CONCLUSION: The incidence of MDS increased over time due to improved notification and better disease awareness, and has stabilised since 2007. The classification of MDS seems challenging as almost half of the pathologically confirmed cases were unspecified. The lack of improvement in survival might be explained by the limited availability of therapeutic agents. Therefore, ameliorated management and new treatment options are warranted.
Authors: A G Dinmohamed; Y van Norden; O Visser; E F M Posthuma; P C Huijgens; P Sonneveld; A A van de Loosdrecht; M Jongen-Lavrencic Journal: Leukemia Date: 2015-09-15 Impact factor: 11.528
Authors: Michael Desborough; Lise J Estcourt; Anna Chaimani; Carolyn Doree; Sally Hopewell; Marialena Trivella; Andreas V Hadjinicolaou; Paresh Vyas; Simon J Stanworth Journal: Cochrane Database Syst Rev Date: 2016-01-26
Authors: T Bernal; P Martínez-Camblor; J Sánchez-García; R de Paz; E Luño; B Nomdedeu; M T Ardanaz; C Pedro; M L Amigo; B Xicoy; C del Cañizo; M Tormo; J Bargay; D Valcárcel; S Brunet; L Benlloch; G Sanz Journal: Leukemia Date: 2015-05-06 Impact factor: 11.528
Authors: Zaher K Otrock; Nabil Chamseddine; Ziad M Salem; Tarek Wehbe; Mouna Al-Ayoubi; Moussa Dhaini; Joseph Kattan; Walid Mokaddem; Therese Abi Nasr; Oussama Jradi; Fadi S Farhat; Mahmoud Wehbe; Mohammad H Haidar; Mohamed A Kharfan-Dabaja; Nizar Bitar; Mirna El Hajj; Adel M Kadri; Francois G Kamar; Hanan Yassine; Hassan Khodr; Ali T Taher; Noha Hakime; Rami Ar Mahfouz; Wassim Serhal; Ali Bazarbachi; Hussein Z Farhat Journal: Am J Blood Res Date: 2015-12-25
Authors: Michael Desborough; Andreas V Hadjinicolaou; Anna Chaimani; Marialena Trivella; Paresh Vyas; Carolyn Doree; Sally Hopewell; Simon J Stanworth; Lise J Estcourt Journal: Cochrane Database Syst Rev Date: 2016-10-31